Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy

Sandra Van Lint, Cleo Goyvaerts, Sarah Maenhout, Lode Goethals, Aurélie Disy, Daphné Benteyn, Joeri Pen, Aude Bonehill, Carlo Heirman, Karine Breckpot, Kris Thielemans

Research output: Contribution to journalArticlepeer-review

147 Citations (Scopus)


The use of tumor-associated antigen (TAA) mRNA for therapeutic purposes is under active investigation. To be effective, mRNA vaccines need to deliver activation stimuli in addition to TAAs to dendritic cells (DC). In this study, we evaluated whether intranodal delivery of TAA mRNA together with TriMix, a mix of mRNA encoding CD40 ligand, constitutive active Toll-like receptor 4 and CD70, results in the in situ modification and maturation of DCs, hence, priming of TAA-specific T cells. We showed selective uptake and translation of mRNA in vivo by lymph node resident CD11c(+) cells. This process was hampered by codelivery of classical maturation stimuli but not by TriMix mRNA. Importantly, TriMix mRNA induced a T-cell-attracting and stimulatory environment, including recruitment of antigen-specific CD4(+) and CD8(+) T cells and CTLs against various TAAs. In several mouse tumor models, mRNA vaccination was as efficient in CTL induction and therapy response as vaccination with mRNA-electroporated DCs. Together, our findings suggest that intranodal administration of TAA mRNA together with mRNA encoding immunomodulating molecules is a promising vaccination strategy.
Original languageEnglish
Pages (from-to)1661-1671
Number of pages11
JournalCancer Research
Publication statusPublished - 1 Apr 2012


  • TriMix
  • Antitumor Therapy


Dive into the research topics of 'Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy'. Together they form a unique fingerprint.

Cite this